These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26788583)

  • 21. Towards better patient care: drugs to avoid.
    Prescrire Int; 2013 Apr; 22(137):108-11. PubMed ID: 23662325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug evaluation by the French National Health Authority for reimbursement decisions].
    Bouvenot G
    Bull Acad Natl Med; 2005 Nov; 189(8):1683-90; discussion 1690-1. PubMed ID: 16737094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs and indications in 2011. France is better focused on patients' interests after the Mediator scandal, but stagnation elsewhere.
    Prescrire Int; 2012 Apr; 21(126):106-10. PubMed ID: 22515141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sales representatives: a damning report by Prescrire reps monitoring network.
    Prescrire Int; 1999 Jun; 8(41):86-9. PubMed ID: 10558452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generic versus brand name drugs in psychopharmacology: a pharmacoeconomic perspective.
    Emanuele E
    South Med J; 2011 Oct; 104(10):715-6. PubMed ID: 21941163
    [No Abstract]   [Full Text] [Related]  

  • 26. "Drugs to avoid" to improve quality use of medicines: how is Australia faring?
    Vitry A; Mintzes B
    J Pharm Policy Pract; 2021 Jul; 14(1):60. PubMed ID: 34256874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New drugs and indications in 2010: inadequate assessment; patients at risk.
    Prescrire Int; 2011 Apr; 20(115):105-7, 109-10. PubMed ID: 21648217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards better patient care: drugs to avoid in 2017.
    Prescrire Int; 2017 Apr; 26(181):108-111. PubMed ID: 30730665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunization: process of elaborating guidelines and their evolution in France].
    Floret D
    Ann Pharm Fr; 2009 May; 67(3):219-23. PubMed ID: 19446673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacoeconomic analyses--chance or 4th hurdle for innovative drugs].
    Krammer H
    Wien Med Wochenschr; 2006 Dec; 156(23-24):606-11. PubMed ID: 17211764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RATIONAL PHARMACOTHERAPY ON THE BASIS OF PHARMACOECONOMIC JUSTIFICATION AND MARKETING RESEARCH ON THE APPLICATION OF IMMUNOMODULATORY PHYTOPREPARATIONS.
    Voskoboinikova HL; Konovalova LV; Dovzhuk VV; Dovzhuk NS
    Wiad Lek; 2023; 76(4):824-830. PubMed ID: 37226622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards better patient care: drugs to avoid in 2014.
    Prescrire Int; 2014 Jun; 23(150):161-5. PubMed ID: 25121155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study.
    Lexchin J
    PLoS One; 2024; 19(8):e0308118. PubMed ID: 39088553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of drugs in therapeutic strategies].
    Castaigne A
    Rev Prat; 2002 Mar; 52(5):491-6. PubMed ID: 11949500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoepidemiological research using French reimbursement databases: yes we can!
    Martin-Latry K; Bégaud B
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):256-65. PubMed ID: 20128015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
    Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
    J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
    Cleemput I; van Wilder P; Huybrechts M; Vrijens F
    Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.